The global defibrillators market was valued at USD 10.9 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 8.6% from 2021 to 2028.. Rising adherence of integrated technology, incidences of cardiac disorders, awareness regarding the importance of good cardiac health, and legislative reforms are the key growth drivers for this market.
In the wake of COVID-19, the International Liaison Committee on Cardiopulmonary Resuscitation (ILCOR) changed the resuscitation guidelines during the pandemic. It suggested improving defibrillation delivery by providing training to healthcare workers which can reduce the confusion as well as delay in COVID-19 resuscitation efforts. The training would also ensure that healthcare providers are not exposed to additional risks and patients suffering from tachyarrhythmic arrests can also be provided their first and best chance of survival.
Furthermore, defibrillators were found to be extremely useful in reviving sudden cardiac arrest in COVID19 which further pushed for the demand for defibrillators in the pandemic situation. Timely supportive regulations and increasing adoption is further anticipated to provide this market with a lucrative growth platform in the next few years.
As per the National Heart, Lung, and Blood Institute (2020), in the U.S. more than 2, 50,000 people die every year due to sudden cardiac arrest. All the states within the U.S. have supported and enforced broad public access laws for reducing deaths due to sudden cardiac arrest. According to American Heart Association, every year around 20,000 lives are saved due to the availability of defibrillators publicly. The state also recommended that Public Access Defibrillators (PADs) must be available in the public holdings, transportation centers, and residential apartments.
In the U.K., a training program for students was introduced, which was conducted by the Advanced Coronary Treatment (ACT) Foundation in association with British Columbia Emergency Health Services (BCEHS) in secondary schools. BCEHS has paramedic volunteers who train teachers to educate students. In certain schools, they are planning to introduce defibrillator training as a part of the physical education curriculum. Such initiatives, help in increasing awareness regarding cardiac conditions and availability of treatment options, such as defibrillators, hence boosting the market growth.
Collaborations, partnerships, acquisitions, product approvals, and launches have significantly impacted the market in recent years. Furthermore, there has been a significant increase in the demand for defibrillators due to its increasing awareness which in turn is fueling the market growth.
The ICD segment dominated the market and accounted for more than 75.0% share of the global revenue in 2020. The growing demand for ICDs for patients with nonischemic cardiomyopathy significantly improved the survival rate and thereby reduces the risk of mortality which is expected to offer opportunities for the ICD manufactures, hence fueling the market growth. The ICD segment is further divided into S-ICD and T-ICD. T-ICDs are further segmented into a single chamber, dual-chamber, and CRT-D.
The external defibrillator segment is expected to show lucrative growth over the forecast period. The segment is further classified into manual EDs, automated EDs, and wearable cardioverter-defibrillators. The rapid innovations and advancements in automated ED technology and the introduction of novel products by key manufactures for enhancing their presence in the market are pushing the development of the external defibrillator market throughout the world. For instance, in September 2019, Shenzhen Mindray Bio-Medical Electronics Co. Ltd. launched the BeneHeart C Series AED for improving resuscitation during sudden cardiac arrest (SCA) cases.
The hospital segment dominated the market and accounted for the largest revenue share of over 89.0% in 2020. This is because hospitals are the primary point of care for the treatment of any type of disease, including cardiac arrests. According to the Centers for Disease Control and Prevention (CDC), as of September 2020, approximately 655,000 Americans are dying suffering from cardiovascular disease every year.
On the other hand, the public access market segment is estimated to register the fastest CAGR of around 8.6% over the forecast period owing to the increasing installation of defibrillators at public places. According to the National Institutes of Health, approximately 18,000 Americans have a shockable cardiac arrest in public and out of hospitals with witnesses. It also estimates that 1,700 victims are saved annually by bystanders using an automated external defibrillator rather than waiting for emergency medical services. Such factors are expected to drive market growth.
North America dominated the defibrillator market and accounted for a revenue share of 35.0% in 2020. This is because several companies present in the region, especially in the U.S. are taking up initiatives to improve public access to defibrillators. Europe is anticipated to be the second-largest market for defibrillators owing to the increasing incidence rate of cardiovascular diseases as well as the presence of a huge target population base.
Asia Pacific is expected to expand at the fastest CAGR over the forecast period owing to the presence of rapidly growing economies such as India and China. Also, countries such as Japan have a high penetration of defibrillators, which further boosts the market growth during the forecast period. Companies are also looking to expand their geographical footprint in the region.
Within the Latin American region, Brazil is expected to demonstrate significant growth as the country has a very high population suffering from sudden cardiac arrests. Also, the overall healthcare system of Brazil is improving, which fuels the market growth. Furthermore, Saudi Arabia and UAE are considered the largest markets for medical devices in the Middle East, which fuels the market growth in the region.
The market leaders are involved in acquisitions, strategic collaborations, and new product launches to withstand the competition. Major market players are investing in acquisitions and launching new products to enhance their position in the market. For instance, in July 2020, Abbott received the U.S. Food and Drug Administration (FDA) clearance for its Gallant ICD and CRT-D devices. This enabled the company to market the device in the U.S. while expanding its portfolio. Some of the prominent players in the defibrillator market include:
Medtronic
Abbott
Boston Scientific Corporation
Stryker
Koninklijke Philips N.V.
Zoll Medical Corporation
Biotronik, Inc.
Nihon Kohden Corporation
Progetti Srl
Schiller
MS Westfalia GmbH
AMI Italia
Axion Ltd.
Bexen Cardio
Report Attribute |
Details |
The market size value in 2021 |
USD 13.3 billion |
Revenue forecast in 2028 |
USD 22.2 billion |
Growth Rate |
CAGR of 8.6% from 2021 to 2028 |
Base year for estimation |
2020 |
Historical data |
2016 - 2019 |
Forecast period |
2021 - 2028 |
Quantitative units |
Revenue in USD million and CAGR from 2021 to 2028 |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
Segments covered |
Product, end-use, region |
Regional Scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country Scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Japan; China; India; Australia; South Korea; Brazil; Mexico; Argentina; Colombia; South Africa; Saudi Arabia; UAE |
Key companies profiled |
Medtronic; Abbott; Boston Scientific Corporation; Stryker; Koninklijke Philips N.V.; Zoll Medical Corporation; Biotronik, Inc.; Nihon Kohden Corporation; Progetti Srl; Schiller; MS Westfalia GmbH; AMI Italia; Axion Ltd.; Bexen Cardio |
Customization scope |
Free report customization (equivalent up to 8 analysts’ working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research has segmented the global defibrillator market report on the basis of product, end-use, and region:
Product Outlook (Revenue, USD Million, 2016 - 2028)
Implantable Cardioverter Defibrillator
S-ICD
T-ICD
Single Chamber
Dual Chamber
CRT-D
External Defibrillator
Manual ED
Automated ED
Wearable Cardioverter Defibrillators
End-use Outlook (Revenue, USD Million, 2016 - 2028)
Hospital
Pre Hospital
Public Access Market
Alternate Care Market
Home Healthcare
Regional Outlook (Revenue, USD Million; 2016 - 2028)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Asia Pacific
Japan
China
India
Australia
South Korea
Latin America
Brazil
Mexico
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
b. The global defibrillator market size was estimated at USD 10.9 billion in 2020 and is expected to reach USD 13.3 billion in 2021.
b. The global defibrillator market is expected to grow at a compound annual growth rate of 8.6% from 2021 to 2028 to reach USD 22.2 billion by 2028.
b. North America dominated the defibrillator market with a share of 35.30% in 2019. This is attributable to the increasing incidence of cardiovascular diseases, supportive government policies, favorable reimbursement schemes, increasing awareness, and an increase in training programs.
b. Some key players operating in the global defibrillator market include Medtronic; St. Jude Medical LLC; Boston Scientific Corporation; LivaNova; Koninklijke Philips N.V.; ZOLL Medical Corporation; Cardiac Science; Physio-Control Inc.; Nihon Kohden Corporation; Defibtech LLC; HeartSine Technologies LLC; Progetti Srl; Fukuda Denshi Co., Ltd.; and Schiller AG.
b. Key factors that are driving the global defibrillator market growth include increasing demand due to supportive legislation policies by the government, the prevalence of cardiovascular diseases coupled with rising awareness about the disease, and demand for treatment of sudden cardiac arrest (SCA).
b. The coronavirus pandemic led to an increased prevalence of sudden cardiac arrests among the affected patients, which increased the demand for the defibrillator market exponentially as a means of resuscitation.
b. The Implantable Cardioverter Defibrillator (ICD) segment dominated the defibrillator market with more than 75% revenue share in 2020, in terms of product.
b. The external defibrillator segment is expected to show lucrative growth in the defibrillator market over the forecast period, owing to rapid innovations and the introduction of novel products at a healthy pace in the industry.
b. The public access market segment is estimated to register the fastest CAGR of around 8.6% over the forecast period in the defibrillator market, aided by the growing product installation at public places.
b. In July 2020, Abbott received the U.S. Food and Drug Administration (FDA) clearance for its Gallant ICD and CRT-D devices, enabling the company to expand its portfolio in the United States.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.